Comparison · NCT01325181-3ef7ab36
Low-fluence PDT vs Ranibizumab: Number of Participants That Achieved Complete Resolution of Subretinal Fluid on OCT Without Rescue Treatment
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Low-fluence PDT vs Ranibizumab: Number of Participants That Achieved Complete Resolution of Subretinal Fluid on OCT Without Rescue Treatment. Trial comparisons, record NCT01325181-3ef7ab36. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01325181-3ef7ab36
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.889 | 0.672 | 0.969 | wilson | |
| Risk in group 2 | 0.125 | 0.035 | 0.36 | wilson | |
| Risk difference, group 1 minus group 2 | 0.764 | 0.444 | 0.884 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 7.11 | 1.93 | 26.3 | log | |
| Odds ratio, group 1 over group 2 | 56 | 6.95 | 451 | log | |
| Number needed to treat, for one more participant with the outcome on Low-fluence PDT than on Ranibizumab | 1.31 | 1.13 | 2.25 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Low-fluence PDT | 16 | 18 | OG000 | |
| Group 2 | Ranibizumab | 2 | 16 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants That Achieved Complete Resolution of Subretinal Fluid on OCT Without Rescue Treatment
- Description
- number of participants who achieved complete resolution of subretinal fluid on OCT without rescue treatment until the end of the study
- Time frame
- 12 months
- Population
- All study eyes were analyzed using intention to treat principle and the last observation forward method
Source ClinicalTrials.gov
Trial
- Title
- Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy
- NCT number
- NCT01325181
- Phases
- PHASE1, PHASE2
- Conditions
- Chronic Central Serous Chorioretinopathy
- Interventions
- Verteporfin, ranibizumab
- Lead sponsor
- Jang Won Heo
- Results first posted
- 2013-05-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01325181?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01325181-3ef7ab36